Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$485.42 USD

485.42
904,979

+3.15 (0.65%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)

Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?

IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.

Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up

Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.

BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence

BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

Owing to the impact of the Russia-Ukraine war situation, supply chain constraints, as well as the inflationary situation, we expect Bio-Rad's (BIO) Life Science arm to experience a year-over-year decline.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Align Technology's (ALGN) Invisalign First for kids is gaining market share rapidly across all regions.

Snehadri Nag headshot

Grab These Top 4 Defensive Stocks to Beat the Market Doldrums

Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water (CWCO), Archer Daniels Midland (ADM) and McKesson (MCK) with strong prospects to beat the market volatility.

Will Boston Scientific (BSX) Beat Q3 Earnings Estimates?

Boston Scientific's (BSX) top line is likely to have improved with non-COVID elective medical procedures running in a full-fledged way in the United States and across the globe.

What's in Store for Thermo Fisher (TMO) in Q3 Earnings?

In terms of performance in high-growth and emerging markets, in its flagship facility for cell culture media in Grand Island, NY, Thermo Fisher (TMO) completes capacity expansion.

3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

LabCorp (LH) to Report Q3 Earnings: What's in the Cards?

LabCorp's (LH) growth in early development and clinical development are expected to have been offset by central labs on the account of a significant slowdown in COVID-related work.

Is a Beat Likely for Intuitive Surgical (ISRG) in Q3 Earnings?

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ

Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.

Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?

The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Accuray's (ARAY) New Treatment Package to Boost Patient Outcome

Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.